Forget a Cash ISA! I’d buy FTSE 250 dividend stocks in a Stocks and Shares ISA

FTSE 250 (INDEXFTSE:MCX) shares could offer a surprisingly high income return compared to a Cash ISA.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

While the FTSE 250 may be viewed as a means to generate high capital growth in the long run, it could offer surprisingly strong income prospects too.

The index yields just 3% at the present time. However, with a Cash ISA offering 1.5% at best, and the FTSE 250’s income return being ahead of inflation, the index could offer an impressive income outlook.

Furthermore, a number of its members could produce high dividend growth rates. It may also be possible to build a diverse portfolio of mid-cap shares that, when combined, have a yield that is significantly higher than 3%.

Growth potential

With the FTSE 250 having recorded annualised total returns of around 9% in the last two decades, the long-term growth potential of the index is clearly high. This growth rate includes two major bear markets (the dotcom bubble and the financial crisis), as well as the recent downturn in performance for the UK economy. In fact, the index currently trades just 8% higher than it did four years ago, with its performance having been negatively impacted by weak investor sentiment following Brexit.

Rising dividends

The growth potential offered by the index’s members may mean that they are able to deliver rapidly-rising dividends. Since they are smaller companies than their FTSE 100 peers, they could produce faster-rising bottom lines that translate into strong dividend growth. Although a portion of their increasing profitability may be used to reinvest for future growth, a part of it could be used to grow their returns to shareholders. As such, the index’s current income return may grow at a relatively brisk pace.

Income prospects

In the near term, it is possible to generate an income return that is significantly higher than the index’s 3% yield from buying its higher-yielding constituents. For example, 54 FTSE 250 shares currently have yields that are in excess of 4.5%. An investor may, therefore, be able to build a portfolio of stocks that together has a combined income return of over 5% in the current year. This could allow an investor to not only generate a higher return than a Cash ISA and the FTSE 100, but also benefit from the long-term growth potential offered by mid-cap shares.

Risks

Of course, the FTSE 250 is a far riskier place to invest when compared to a Cash ISA. It is possible to lose capital on any of the index’s stocks, with risks such as Brexit having the potential to weigh on the performance of what is a UK-focused index.

However, the FTSE 250 has always recovered from bear markets and recessions to post higher highs. This trend is likely to continue in the long run, with its present-day valuation suggesting that it offers a margin of safety. As such, for income investors who have a long-term outlook, it could offer a much more appealing risk/reward ratio than saving through a Cash ISA.

Peter Stephens has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »